Literature DB >> 8367802

Medullary carcinoma of the thyroid--therapeutic strategy derived from fifteen years of experience.

F Kallinowski1, H J Buhr, H Meybier, M Eberhardt, C Herfarth.   

Abstract

BACKGROUND: The purpose of this investigation was to analyze our experience with patients treated for medullary carcinoma of the thyroid to identify prognostic factors and to develop a stage-related treatment strategy that might improve cure rates.
METHODS: Between 1970 and 1985 a total of 40 patients with medullary thyroid carcinoma were treated (21 women, 19 men; mean age +/- SEM; 40 +/- 3 years; mean follow-up, 82 +/- 12 months). Initial operation involved total thyroidectomy (28 patients), subtotal resection (11 patients), and a lobectomy (1 patient). The initial lymph node dissection generally consisted of a selective removal of enlarged nodes. Unilateral neck dissection was performed in six cases. Secondary operation for recurrent disease was necessary in 26 patients.
RESULTS: At the end of the follow-up period 10 patients were tumor free, 12 patients were scheduled for further treatment, six patients suffered from persistent but clinically occult disease, and 12 patients had died (mean survival time, 68 +/- 7 months). The paramount prognostic factor was the absence or presence of lymph node involvement at the time of primary operation (p = 0.011). Patients with distant metastases died within 2 years of diagnosis. Women, patients younger than 40 years of age, and those elicited by familial screening programs exhibited increased survival times.
CONCLUSIONS: Because of the prognostic and therapeutic importance we recommend the total thyroidectomy with a complete dissection of the central lymph node compartment as primary treatment. Patients with lymph node involvement or elevated serum calcitonin levels should subsequently be treated by a modified radical neck dissection of the lateral compartments.

Entities:  

Mesh:

Year:  1993        PMID: 8367802

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

2.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 3.  Surgical strategy for the treatment of medullary thyroid carcinoma.

Authors:  J B Fleming; J E Lee; M Bouvet; P N Schultz; S I Sherman; R V Sellin; K E Friend; M A Burgess; G J Cote; R F Gagel; D B Evans
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

4.  Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.

Authors:  P Gasparoni; D Rubello; G Ferlin
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

5.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

6.  Incidentally found medullary thyroid cancer: treatment rationale for small tumors.

Authors:  Andreas Raffel; Kenko Cupisti; Markus Krausch; Achim Wolf; Klaus-Martin Schulte; Hans-Dietrich Röher
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

Review 7.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.